Timothy Perren - Dissemin

Language
Login

Papers authored by Timothy Perren

This paper was not found in any repository, but could be made available legally by the author.

2015 Sean Kehoe, Jane Hook, Matthew Nankivell, Gordon C. Jayson, Henry C. Kitchener, Tito Lopes, David Luesley, Timothy Perren

ORCID

, Selina Bannoo, Monica Mascarenhas, Stephen Dobbs, Sharadah Essapen, Jeremy Twigg, Jonathan Herod, Glenn McCluggage and 2 other authors

Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial.

Upload

This paper was not found in any repository; the policy of its publisher is unknown or unclear.

2014 Benjamin Pickwell-Smith

ORCID

, Faisal Al-Terkait, Mahaz Kayani, Timothy John Perren

ORCID

, Sheryl Sim

Advances in the Medical Management of Ovarian Cancer

Upload

This paper is available in a repository.

2013 Dan Stark, Matthew Nankivell, Eric Pujade-Lauraine, G. Kirstensen, Gunnar Kristensen, Lorraine Elit, Martin Stockler, Felix Hilpert, Andrés Cervantes, Julia Brown, Anne Lanceley, Galina Velikova, Eduardo Sabate, Jacobus Pfisterer, Mark S. Carey and 5 other authors

Standard chemotherapy with or without bevacizumab in advanced ovarian cancer: quality-of-life outcomes from the International Collaboration on Ovarian Neoplasms (ICON7) phase 3 randomised trial.

Download from www.ncbi.nlm.nih.gov

This paper is made freely available by the publisher.

M. Hall, C. Gourley, I. McNeish

ORCID

, J. Ledermann, M. Gore, G. Jayson, T. Perren

ORCID

, G. Rustin, S. Kaye

Targeted anti-vascular therapies for ovarian cancer: current evidence

Download from www.nature.com

This paper was not found in any repository, but could be made available legally by the author.

2012 Fiona J. Collinson, Jenny Seligmann, Timothy J. Perren

ORCID

Ovarian Cancer: Advances in First-Line Treatment Strategies with a Particular Focus on Anti-Angiogenic Agents

Upload

This paper was not found in any repository; the policy of its publisher is unknown or unclear.

A. M. Oza, A. M. Swart, T. J. Perren

ORCID

Dr. Swart and colleagues reply

Upload

This paper is available in a repository.

2011 Jay D. Naik, Jenny Seligmann, Timothy J. Perren

ORCID

Mucinous tumours of the ovary

Download from www.researchgate.net

This paper is available in a repository.

Ja A. Ledermann, Allan Hackshaw, Stan B. Kaye, Gordon C. Jayson, Hani Gabra, Iain McNeish

ORCID

, Helena Earl, Tim Perren

ORCID

, Martin Gore, Mojca Persic, Malcolm Adams, Lindsay James, Graham Temple, Michael Merger, Gordon J. S. Rustin and 1 other authors

Randomized Phase II Placebo-Controlled Trial of Maintenance Therapy Using the Oral Triple Angiokinase Inhibitor BIBF 1120 After Chemotherapy for Relapsed Ovarian Cancer

Download from www.researchgate.net

This paper is made freely available by the publisher.

Henri Roché, Timothy J. Perren

ORCID

, Miguel Martin, David Miles, Joanne Parker, David A. Cameron, John Glaspy, Alejandro Tres, James Lee Murray, David Dodwell, José Mayordomo, Nuhad K. Ibrahim

Phase III Multicenter Clinical Trial of the Sialyl-TN (STn)-Keyhole Limpet Hemocyanin (KLH) Vaccine for Metastatic Breast Cancer

Download from theoncologist.alphamedpress.org

This paper is made freely available by the publisher.

A. C. Young, B. Mercer, T. J. Perren

ORCID

, D. Dodwell

Anthracycline-induced cardiomyopathy in siblings with early breast cancer

Download from academic.oup.com

This paper is available in a repository.

G. Rustin, N. Reed, Gordon C. Jayson, J. A. Ledermann, M. Adams, T. Perren

ORCID

, Christopher Poole, M. Lind, M. Persic, S. Essapen, M. Gore, H. Calvert, C. Stredder, A. Wagner, M. Giurescu and 1 other authors

A phase II trial evaluating two schedules of sagopilone (ZK-EPO), a novel epothilone, in patients with platinum-resistant ovarian cancer.

Download from www.researchgate.net

This paper was not found in any repository; the policy of its publisher is unknown or unclear.

Muthuramalingam Sr, J. P. Braybrooke, A. D. Blann, S. Wilner, Braybrooke Jp, Ganesan Ts, S. Madhusudan, Blann Ad, S. R. Muthuramalingam, T. Perren

ORCID

, A. Jenkins, C. Han, K. Kaur, T. S. Ganesan

A prospective randomised phase II trial of thalidomide with carboplatin compared with carboplatin alone as a first-line therapy in women with ovarian cancer, with evaluation of potential surrogate markers of angiogenesis

Upload

This paper is available in a repository.

Timothy J. Perren

ORCID

, Andreas du Bois, Ann Marie Swart, Jacobus Pfisterer, Jonathan A. Ledermann, Eric Pujade-Lauraine, Gunnar Kristensen, Mark S. Carey, Philip Beale, Andrés Cervantes, Christian Kurzeder, Andreas du Bois, Jalid Sehouli, Rainer Kimmig, Anne Stähle and 12 other authors

A phase 3 trial of bevacizumab in ovarian cancer

Download from www.nejm.org

This paper is made freely available by the publisher.

2010 B. Sirohi, R. A'Hern, G. Coombes, J. M. Bliss, T. Hickish, T. Perren

ORCID

, M. Crawford, M. O'Brien, T. Iveson, S. Ebbs, A. Skene, R. Laing, I. E. Smith

A randomised comparative trial of infusional ECisF versus conventional FEC as adjuvant chemotherapy in early breast cancer: The TRAFIC trial

Download from academic.oup.com

This paper was not found in any repository, but could be made available legally by the author.

Roshan Agarwal, Charlie Gourley, Timothy J. Perren

ORCID

, Nicholas Reed, David E. Parkin, Karen Carty, Gordon J. S. Rustin, Hani Gabra, Jim Paul, Martin E. Gore, Stanley B. Kaye

First-line therapy for ovarian cancer with carboplatin followed by paclitaxel–gemcitabine (SCOTROC5): A feasibility study and comparative analysis of the SCOTROC series

Upload

This paper is available in a repository.

Janine L. Mansi, Ann Yellowlees, Julian Lipscombe, Helena M. Earl, David A. Cameron, Robert E. Coleman, Timothy Perren

ORCID

, Christopher J. Gallagher, Mary Quigley, John Crown, Alison L. Jones, Martin Highley, Robert C. F. Leonard, T. R. Jeffry Evans

Five-year outcome for women randomised in a phase III trial comparing doxorubicin and cyclophosphamide with doxorubicin and docetaxel as primary medical therapy in early breast cancer: An Anglo-Celtic Cooperative Oncology Group Study

Download from hal.archives-ouvertes.fr

This paper is available in a repository.

Naveen S. Vasudev

ORCID

, Ioannis Trigonis, David A. Cairns, Geoff D. Hall, David P. Jackson, Timothy Broadhead, John Buxton, Richard Hutson, Geoffrey Lane, David Nugent, Timothy J. Perren

ORCID

The prognostic and predictive value of CA-125 regression during neoadjuvant chemotherapy for advanced ovarian or primary peritoneal carcinoma

Download from www.ncbi.nlm.nih.gov

This paper was not found in any repository, but could be made available legally by the author.

Adam J. W. Paige, Manuela Zucknick, Szymon Janczar, Jim Paul, Charles A. Mein, Karen J. Taylor, Moira Stewart, Charlie Gourley, Sylvia Richardson, Timothy Perren

ORCID

, Trivadi S. Ganesan, John F. Smyth, Robert Brown, Hani Gabra

WWOX tumour suppressor gene polymorphisms and ovarian cancer pathology and prognosis

Upload

This paper is made freely available by the publisher.

John A. Spencer, Timothy J. Perren

ORCID

Recent EORTC and MRC UK studies: implications for imaging ovarian cancer

Download from dx.doi.org

This paper was not found in any repository, but could be made available legally by the author.

2009 S. H. Waters

ORCID

, A. Gillibrand, H. Berry, S. Kumar, G. Velikova, D. J. Dodwell, Timothy J. Perren

ORCID

Dose-finding study of weekly docetaxel, epirubicin and capecitabine, as first-line treatment in advanced breast cancer

Upload

Missing publications? Search for publications with a matching author name.